Novel group I/group II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPG (Cat. No. 0336).
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 100 mM in 1.1eq. NaOH|
Preparing Stock Solutions
The following data is based on the product molecular weight 223.23. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.48 mL||22.4 mL||44.8 mL|
|5 mM||0.9 mL||4.48 mL||8.96 mL|
|10 mM||0.45 mL||2.24 mL||4.48 mL|
|50 mM||0.09 mL||0.45 mL||0.9 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Bedingfield et al (1995) Structure-activity relationships for a series of phenylglycine derivatives acting at metabotropic glutamate receptors (mGluRs). Br.J.Pharmacol. 116 3323 PMID: 8719814
Sekiyama et al (1996) Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br.J.Pharmacol. 117 1493 PMID: 8730745
If you know of a relevant reference for E4CPG, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Group II group I mGlur antagonists Receptors mGlu2 mGlu3 mGluR2 mGluR3 Glutamate Metabotropic mGlu1 mGlu5 mGluR1 mGluR5 Glutamate (Metabotropic) Group I Receptors
1 Citation for E4CPG
Citations are publications that use Tocris products. Selected citations for E4CPG include:
Newman (2005) Calcium increases in retinal glial cells evoked by light-induced neuronal activity. Neuropharmacology 25 5502 PMID: 15944378
Do you know of a great paper that uses E4CPG from Tocris? If so please let us know.
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.